Contrasting Genprex (NASDAQ:GNPX) & Avadel Pharmaceuticals (NASDAQ:AVDL)

Avadel Pharmaceuticals (NASDAQ:AVDL) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and target prices for Avadel Pharmaceuticals and Genprex, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avadel Pharmaceuticals	0	0	7	0	3.00
Genprex	0	0	1	0	3.00

Avadel Pharmaceuticals presently has a consensus price target of $21.00, indicating a potential upside of 152.10%. Genprex has a consensus price target of $10.00, indicating a potential upside of 1,900.00%. Given Genprex’s higher probable upside, analysts plainly believe Genprex is more favorable than Avadel Pharmaceuticals.

Institutional & Insider Ownership

69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 8.5% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Avadel Pharmaceuticals and Genprex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avadel Pharmaceuticals	-52.53%	-93.34%	-44.77%
Genprex	N/A	-409.48%	-269.17%

Risk & Volatility

Avadel Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Genprex has a beta of -0.96, indicating that its share price is 196% less volatile than the S&P 500.

Earnings & Valuation

This table compares Avadel Pharmaceuticals and Genprex”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avadel Pharmaceuticals	$138.16 million	5.81	-$160.28 million	($0.79)	-10.54
Genprex	N/A	N/A	-$30.86 million	N/A	N/A

Genprex has lower revenue, but higher earnings than Avadel Pharmaceuticals.

Summary

Avadel Pharmaceuticals beats Genprex on 6 of the 10 factors compared between the two stocks.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

About Genprex

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.